Home-based transcranial direct current stimulation for major depression
Official title: Home-Based Transcranial Direct Current Stimulation in Major Depressive Disorder: a Multi-Centre, Two-Parallel Group, Superiority Randomised Controlled Trial
Run by King's College London · NCT07228468 · Data updated 2026-11-12
This trial will test whether using a small brain-stimulation device at home (tDCS) together with usual care helps adults with moderate-to-severe major depressive disorder feel better over a 10-week treatment and up to six months of follow-up.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 438 (estimated) |
| Sponsor | King's College London Academic / other |
| Locations | 6 sites (Cardiff and 5 other locations) |
| Status | Recruiting |
| Started | November 18, 2025 |
| Main results expected | May 15, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | January 26, 2026 |
| Trial ID | NCT07228468 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or over with a current DSM-5 diagnosis of major depressive disorder, at least moderate symptom severity (MADRS ≥ 18), who are either medication-free or on a stable antidepressant dose and able to provide informed consent and engage with NHS follow-up are ideal candidates.
✕Probably not a fit
People with significant suicide risk, unstable medical or psychiatric comorbidity, or other contraindications to tDCS are unlikely to benefit or be eligible for this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multi-centre, pragmatic randomized controlled trial comparing 10 weeks of active home-based transcranial direct current stimulation (tDCS) plus treatment as usual (TAU) versus TAU alone. About 438 adults with DSM-5 major depressive disorder and at least moderate symptoms will be randomized and followed for six months from treatment start. The primary outcome is clinician-rated depressive symptoms (MADRS); secondary outcomes include self-report mood, anxiety, remission rates, acceptability, quality of life, and health economic measures. The trial includes process and implementation work to examine feasibility and pathways for integrating home tDCS into NHS care.
Why it matters
Potential benefit: If successful, home tDCS could provide an effective, non-drug, scalable treatment option that reduces depressive symptoms and improves quality of life for patients who prefer alternatives to or who do not fully respond to current treatments.
How similar studies have gone: Clinic-based tDCS studies have produced mixed but promising results and small home-based pilot studies show feasibility, but large definitive RCT evidence for home tDCS is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults aged 18 years or over 2. Current episode of depression based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (APA, 2013) for major depressive disorder (MDD) as assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 3. Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS 4. Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment. 5. Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment. 6. Being under the care of GP 7. Agreeable for GP to be regularly informed about study participation 8. Able to provide written, informed consent Exclusion Criteria: 1. Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011) 2. Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM-5 criteria as assessed in MINI 3. Current daily use of medications that affect cortical excitability (e.g. benzodiazepines) 4. Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of 8 or more in Alcohol use disorders identification test consumption (AUDIT C) (Khadjesari et al., 2017; NICE, 2023) 5. History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation 6. History of esketamine / ketamine for treatment of depression 7. History of psychosurgery for depression 8. Having cognitive impairment (e.g. dementia) 9. Current medical disorder or neurological disorder that may mimic mood disorder (e.g. hormonal disorder, unstable heart disease) 10. Have any implant in the brain or neurocranial defect 11. Have shrapnel or any ferromagnetic material in the head 12. Have any active implantable medical device (e.g. pacemaker) 13. If female and of child-bearing potential, currently pregnant or planning to become pregnant during the study 14. Concurrent enrolment in another interventional study
Where it's running
-
South London and Maudsley NHS Foundation Trust
London, United Kingdom Recruiting -
Cardiff and Vale Health Board
Cardiff, United Kingdom Not yet recruiting -
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
Newcastle, United Kingdom Not yet recruiting -
Northamptonshire Healthcare NHS Foundation Trust
Northampton, United Kingdom Not yet recruiting -
Nottinghamshire Healthcare NHS Foundation Trust
Nottingham, United Kingdom Not yet recruiting -
Hampshire and Isle of Wight Healthcare NHS Foundation Trust
Southampton, United Kingdom Not yet recruiting
Study contacts
- Principal investigator: Cynthia Fu, MD, PhD — King's College London
- Study coordinator: Cynthia Fu
- Email: cynthia.fu@kcl.ac.uk
- Phone: 020 7848 0002
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Temporally Interfering Electrical Stimulation for Major Depressive Disorder
This study tests whether noninvasive temporally interfering electrical stimulation can help people with major depressive disorder.
-
Affective Cognitive Training for mood disorders and their close relatives
A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.
-
ALKS 7290 added to antidepressants for adults with major depression
This study tests whether ALKS 7290, taken with current antidepressants, helps adults with major depressive disorder.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
EEG-Guided TMS for Adults With Depression
This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.